MGEN News and Press, Miragen Therapeutics Inc. From 10/28/20

MiRagen Therapeutics (MGEN) shoots 156% premarket after completing the acquisition of privately held Viridian Therapeutics in a stock-for-stock transaction.All of Viridian’s outstanding equity interests were exchanged for a combination of miRagen common stock and Series ...

Acquisition includes clinical stage anti-IGF - 1R monoclonal antibody, VRDN-001 , intended for the treatment of thyroid eye disease (TED) Company plans to use p rivate placement financing p roceeds of $ 91 million to advance mu...

Looking For Penny Stocks On Robinhood? 4 To Watch This Week Whether you’re looking for penny stocks on Robinhood , Webull, TD, Etrade, Interactive Brokers, or any of the other online trading platforms, the goal’s the same. Make money then repeat the process. That might...

Preliminary data from a Phase 2 clinical trial, SOLAR, evaluating miRagen Therapeutics' (MGEN) cobomarsen in patients with cutaneous T-cell lymphoma ((CTCL)) failed to demonstrate a likelihood that the study would achieve the primary endpoint of objective skin response of at least four months...

BOULDER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it has conducted an internal review of preliminary topline data fr...

miRagen Therapeutics (NASDAQ: MGEN ) has appointed Lee Rauch, as President, Chief Executive Officer and a Director, following the resignation of William Marshall, though he has agreed to act as Senior Technical Advisor. More news on: Miragen Therapeutics, Inc., Healthcare sto...

Lee Rauch appointed President and CEO, following resignation by William Marshall miRagen will undertake an in-depth review of its portfolio Ladenburg Thalmann engaged as financial advisor BOULDER, Colo., Sept. 14, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGE...

BOULDER, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a ...

miRagen Therapeutics, Inc. (MGEN) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors Bill Marshall – President and Chief Executive Officer Diana Escolar – Chief Medical Officer Jaso...

Miragen Therapeutics (NASDAQ: MGEN ) : Q2 GAAP EPS of -$0.12 beats by $0.05 . More news on: Miragen Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...